GlassScriptPhysician profile
Gina P Spohn
NPI 1952729774
$3,561.36
in general payments reported to CMS, 2019-2025
30 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $162 · 2021: $347 · 2022: $454 · 2023: $427 · 2024: $278 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.38 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $576.64 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $416.27 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $362.30 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $335.81 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $245.03 | 2019-2025 | |
| Janssen Biotech, INC. | $239.37 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $236.55 | 2024-2025 | Bimzelx |
| Allergan, INC. | $146.69 | 2019-2021 | |
| Amgen INC. | $146.11 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $119.65 | 2019-2025 | Ebglyss, Taltz |
| Incyte Corporation | $100.57 | 2021-2025 | Opzelura |
| Genzyme Corporation | $70.59 | 2019 | |
| Smith+Nephew, INC. | $65.47 | 2019-2020 | |
| Dermira, INC. | $62.07 | 2019-2020 | |
| Galderma Laboratories, L.P. | $55.61 | 2019-2025 | Aklief, Nemluvio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.39 | 2022-2023 | Spevigo |
| Mayne Pharma Commercial LLC | $47.54 | 2019 | |
| Leo Pharma INC. | $45.44 | 2019-2023 | Adbry |
| Organogenesis INC. | $30.96 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.60 | 2020 | |
| Biocon Biologics INC | $25.03 | 2025 | Yesintek |
| Almirall LLC | $24.10 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.95 | 2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $20.04 | 2025 | Zoryve |
| Genentech USA, INC. | $17.57 | 2019 | |
| Dermavant Sciences, INC. | $16.09 | 2022 | |
| Merck Sharp & Dohme LLC | $14.55 | 2019 | |
| Kyowa Kirin, INC. | $14.03 | 2022 | |
| Promius Pharma LLC | $11.45 | 2019 | |
| Organon LLC | $7.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Spohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.